CNS Pharmaceuticals, Inc. Common Stock (CNSP) is a publicly traded Healthcare sector company. As of May 21, 2026, CNSP trades at $4.98 with a market cap of $3.82M and a P/E ratio of -0.14. CNSP moved +10.88% today. Year to date, CNSP is -3.43%; over the trailing twelve months it is -67.05%. Its 52-week range spans $1.90 to $221.94. Analyst consensus is buy with an average price target of $10.00. Rallies surfaces CNSP's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
CNS Pharmaceuticals Raises $22.5M, Launches Acquisition-Driven Strategy: CNS Pharmaceuticals completed an oversubscribed $22.5 million private placement to fund acquisitions of differentiated clinical-stage assets and out-license legacy glioblastoma programs. The company reported a first quarter net loss of $4.936 million versus $4.301 million a year earlier and held $2.951 million cash pre-financing.
| Metric | Value |
|---|---|
| Price | $4.98 |
| Market Cap | $3.82M |
| P/E Ratio | -0.14 |
| EPS | $-35.75 |
| Dividend Yield | 0.00% |
| 52-Week High | $221.94 |
| 52-Week Low | $1.90 |
| Volume | 40 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-15.85M |
| Gross Margin | 0.00% |
1 analysts cover CNSP: 0 strong buy, 1 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $10.00.